Status:
COMPLETED
Genotype-guided Versus Standard for Warfarin Dosing
Lead Sponsor:
China National Center for Cardiovascular Diseases
Conditions:
Atrial Fibrillation
Valvular Heart Disease
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
To compare the efficiency and safety between gene-oriented group and standard care group during 90 days of initial warfarin-treatment for requiring anticoagulation patients with valve replacement or a...
Detailed Description
Due to narrow therapeutic window, and individual differences in dosage, inappropriate use of warfarin may lead to serious complications and ineffective. Based on the results of the research on the tra...
Eligibility Criteria
Inclusion
- Patients aged from 18 to 70 years old, requiring anticoagulation because of valvular or non-valvular atrial fibrillation or after valvular replacement. Patients could visit to be followed up in our hospital clinic regularly and agree to participate in the clinical trial and sign a written informed consent.
Exclusion
- Patients will be excluded from the trial if aged \<18 years old or \> 75 years old, pregnant and lactating, if treated tricuspid valve replacement, or coronary artery bypass grafting before, if diagnosed with congenital heart disease, if known their CYP2C9 or VKORC1 genotype, if taken dicoumarol drugs previously or taking them now, if not suitable for enrollment judged by researchers.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
560 Patients enrolled
Trial Details
Trial ID
NCT03479684
Start Date
January 1 2017
End Date
December 31 2021
Last Update
April 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese Academy of Medical Sciences Fuwai Hospital
Beijing, Beijing Municipality, China, 100037